-
1
-
-
0027769745
-
Comparison of four basic models of indirect pharmacodynamic responses
-
Dayneka NL, Garg V and Jusko WJ (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokin Biopharm 21: 457-478
-
(1993)
J Pharmacokin Biopharm
, vol.21
, pp. 457-478
-
-
Dayneka, N.L.1
Garg, V.2
Jusko, W.J.3
-
2
-
-
0031319752
-
Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials
-
Sheiner LB, Beal SL and Dunne A (1997). Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. JASA 92: 1235-1255
-
(1997)
JASA
, vol.92
, pp. 1235-1255
-
-
Sheiner, L.B.1
Beal, S.L.2
Dunne, A.3
-
3
-
-
0037384060
-
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
-
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I and Peck CC (2003). Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73: 348-365
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 348-365
-
-
Lee, H.1
Kimko, H.C.2
Rogge, M.3
Wang, D.4
Nestorov, I.5
Peck, C.C.6
-
4
-
-
33846430457
-
Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis
-
Hutmacher MM, Nestorov I, Ludden T, Zitnik R and Banfield C (2007). Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol 47: 238-248
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 238-248
-
-
Hutmacher, M.M.1
Nestorov, I.2
Ludden, T.3
Zitnik, R.4
Banfield, C.5
-
5
-
-
0029858447
-
Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency
-
Johnston JA, Bacon CM, Riedy MC and O'Shea JJ (1996). Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 60: 441-452
-
(1996)
J Leukoc Biol
, vol.60
, pp. 441-452
-
-
Johnston, J.A.1
Bacon, C.M.2
Riedy, M.C.3
O'Shea, J.J.4
-
6
-
-
0242332186
-
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
-
Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ and Borie DC (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878
-
(2003)
Science
, vol.302
, pp. 875-878
-
-
Changelian, P.S.1
Flanagan, M.E.2
Ball, D.J.3
Kent, C.R.4
Magnuson, K.S.5
Martin, W.H.6
Rizzuti, B.J.7
Sawyer, P.S.8
Perry, B.D.9
Brissette, W.H.10
McCurdy, S.P.11
Kudlacz, E.M.12
Conklyn, M.J.13
Elliott, E.A.14
Koslov, E.R.15
Fisher, M.B.16
Strelevitz, T.J.17
Yoon, K.18
Whipple, D.A.19
Sun, J.20
Munchhof, M.J.21
Doty, J.L.22
Casavant, J.M.23
Blumenkopf, T.A.24
Hines, M.25
Brown, M.F.26
Lillie, B.M.27
Subramanyam, C.28
Shang-Poa, C.29
Milici, A.J.30
Beckius, G.E.31
Moyer, J.D.32
Su, C.33
Woodworth, T.G.34
Gaweco, A.S.35
Beals, C.R.36
Littman, B.H.37
Fisher, D.A.38
Smith, J.F.39
Zagouras, P.40
Magna, H.A.41
Saltarelli, M.J.42
Johnson, K.S.43
Nelms, L.F.44
Des Etages, S.G.45
Hayes, L.S.46
Kawabata, T.T.47
Finco-Kent, D.48
Baker, D.L.49
Larson, M.50
Si, M.S.51
Paniagua, R.52
Higgins, J.53
Holm, B.54
Reitz, B.55
Zhou, Y.J.56
Morris, R.E.57
O'Shea, J.J.58
Borie, D.C.59
more..
-
7
-
-
0029044362
-
ACR preliminary definition of improvement in rheumatoid arthritis
-
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S and Lightfoot R Jr (1995). ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727-735
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
Bombardier, C.4
Furst, D.5
Goldsmith, C.6
Katz, L.M.7
Lightfoot Jr., R.8
Paulus, H.9
Strand, V.10
Tugwell, P.11
Weinblatt, M.12
Williams, H.J.13
Wolfe, F.14
Kieszak, S.15
-
8
-
-
34249276510
-
A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis
-
Kremer JM, Bloom BJ, Breedveld FC, Coombs J, Fletcher MP, Gruben D, Krishnaswami S, Burgos R-Vargas, Wilkinson B, Zerbini CAF and Zwillich SH (2006). A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis Rheum 54: 4116
-
(2006)
Arthritis Rheum
, vol.54
, pp. 4116
-
-
Kremer, J.M.1
Bloom, B.J.2
Breedveld, F.C.3
Coombs, J.4
Fletcher, M.P.5
Gruben, D.6
Krishnaswami, S.7
R-Vargas, B.8
Wilkinson, B.9
Zerbini, C.A.F.10
Zwillich, S.H.11
-
9
-
-
0030429755
-
Characterization of four basic models of indirect pharmacodynamic responses
-
Sharma A and Jusko WJ (1996). Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokin Biopharm 24: 611-635
-
(1996)
J Pharmacokin Biopharm
, vol.24
, pp. 611-635
-
-
Sharma, A.1
Jusko, W.J.2
-
11
-
-
0347932020
-
A two-part mixture model for longitudinal adverse event severity data
-
Kowalski KG, McFadyen L, Hutmacher MM, Frame B and Miller R (2003). A two-part mixture model for longitudinal adverse event severity data. J Pharmacokin Pharmacodynam 30: 315-336
-
(2003)
J Pharmacokin Pharmacodynam
, vol.30
, pp. 315-336
-
-
Kowalski, K.G.1
McFadyen, L.2
Hutmacher, M.M.3
Frame, B.4
Miller, R.5
-
12
-
-
43949143747
-
Two-step population analysis of pregabalin exposure-adverse event severity in patients with neuropathic pain, generalized anxiety disorder, or partial seizures
-
Salt Lake City, Utah, USA, October
-
Liu J, Kowalski KG, Bockbrader HN, Burger PJ, Corrigan BW, Hermann D, Frame B, Lalonde LR, Miller R (2003) Two-step population analysis of pregabalin exposure-adverse event severity in patients with neuropathic pain, generalized anxiety disorder, or partial seizures. AAPS Annual Meeting. Salt Lake City, Utah, USA, October, pp 26-30
-
(2003)
AAPS Annual Meeting
, pp. 26-30
-
-
Liu, J.1
Kowalski, K.G.2
Bockbrader, H.N.3
Burger, P.J.4
Corrigan, B.W.5
Hermann, D.6
Frame, B.7
Lalonde, L.R.8
Miller, R.9
-
13
-
-
0031467709
-
Random effects probit and logistic regression models for three-level data
-
Gibbons RD and Hedeker D (1997). Random effects probit and logistic regression models for three-level data. Biometrics 53: 1527-1537
-
(1997)
Biometrics
, vol.53
, pp. 1527-1537
-
-
Gibbons, R.D.1
Hedeker, D.2
-
14
-
-
0001306637
-
Regression models for ordinal data
-
McCullagh P (1980). Regression models for ordinal data. Statist J R Soc B 42: 109-142
-
(1980)
Statist J R Soc B
, vol.42
, pp. 109-142
-
-
McCullagh, P.1
-
15
-
-
0031019908
-
Pathogenesis of rheumatoid arthritis
-
Weyand CM and Goronzy JJ (1997). Pathogenesis of rheumatoid arthritis. Med Clin North Am 81: 29-55
-
(1997)
Med Clin North Am
, vol.81
, pp. 29-55
-
-
Weyand, C.M.1
Goronzy, J.J.2
-
17
-
-
28444480672
-
Collapsing mechanistic models: An application to dose selection for proof of concept of a selective irreversible antagonist
-
Hutmacher MM, Mukherjee D, Kowalski KG and Jordan DC (2005). Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist. J Pharmacokin Pharmacodynam 32: 501-520
-
(2005)
J Pharmacokin Pharmacodynam
, vol.32
, pp. 501-520
-
-
Hutmacher, M.M.1
Mukherjee, D.2
Kowalski, K.G.3
Jordan, D.C.4
-
18
-
-
0018394195
-
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to D-turbocurarine
-
Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to D-turbocurarine. Clin Pharmacol Ther 25: 358-371
-
(1979)
Clin Pharmacol Ther
, vol.25
, pp. 358-371
-
-
Sheiner, L.B.1
Stanski, D.R.2
Vozeh, S.3
Miller, R.D.4
Ham, J.5
|